ICON plc — FY2020 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2020, compared primarily with FY2019. This is an annual report, not a standalone fourth-quarter filing. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Business context and key financial metrics
ICON is an Ireland-based global contract research organization (CRO), providing clinical development, laboratory, consulting and related services to pharmaceutical, biotechnology, medical-device and government customers. At year-end it had approximately 15,730 employees across 93 locations in 41 countries.
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $2,797.3 million | $2,805.8 million | Down 0.3% (down 0.5% constant currency) |
| Operating income | $391.5 million | $433.4 million | Down 9.7% |
| Operating margin | 14.0% | 15.4% | Down 1.4 percentage points |
| Operating income excluding restructuring | $409.6 million | $433.4 million | Down 5.5%; margin 14.6% versus 15.4% |
| Net income attributable to the Group | $332.3 million | $374.0 million | Down 11.1% |
| Diluted EPS | $6.15 | $6.79 | Down 9.4% |
| Net cash from operating activities | $568.0 million | $412.5 million | Up $155.5 million |
| Cash and cash equivalents | $840.3 million | $520.3 million | Up $320.0 million |
| Working capital | $979.0 million | $493.7 million | Up $485.3 million |
| Total assets | $3,435.6 million | $2,907.5 million | Up $528.1 million |
| Shareholders’ equity | $1,850.2 million | $1,618.1 million | Up $232.2 million |
Direct costs were 70.8% of revenue, compared with 70.4% in FY2019. The filing reports $350 million principal amount of senior notes outstanding; the 2020 notes replaced notes that matured during the year. Cash plus short-term investments was $842.0 million, implying approximately $492 million of net cash against senior-note principal, before considering leases and other liabilities. The $150 million revolving credit facility was undrawn at year-end.
Material changes versus FY2019
- COVID-19 disruption constrained on-site monitoring, travel, patient access and timely collection and analysis of laboratory samples, with the strongest reported impact in late Q1 and Q2. COVID-related trial work partially offset the effect later in the year.
- Operating margin declined amid higher direct costs, SG&A, depreciation and amortization, and an $18.1 million restructuring charge; FY2019 had no restructuring charge. Excluding restructuring, operating income still declined 5.5%.
- Operating cash flow rose to $568.0 million. Days’ revenue outstanding fell to 57 from 72, while unearned revenue increased to $660.9 million from $367.0 million, partly reflecting advance billings on larger vaccine trials.
- ICON spent $175.0 million repurchasing 1.24 million shares. The year-end share count was 52.79 million versus 53.62 million a year earlier.
- FY2020 acquisitions and investments included MedPass for $47.6 million and a 49% interest in oncology site-network venture Oncacare. ICON also paid $43.9 million to acquire the remaining MeDiNova interest.
Outlook, management commentary, risks and unusual items
- Outlook: The filing gives no specific FY2021 revenue or earnings guidance. Management expected approximately $60 million of capital spending over the next 12 months, principally for IT, facility expansion and new offices, and stated it expected to fund foreseeable needs from operating cash flow, cash balances and available facilities. It considered liquidity adequate for at least 12 months and did not expect COVID-19 to significantly affect overall liquidity.
- Contracted work: Unsatisfied performance obligations were approximately $6.3 billion at year-end; ICON expected about 42% to be recognized over the next 12 months. Management cautioned that project cancellation or delay means this is not assured revenue.
- COVID-19 activity: ICON reported monitoring and safety oversight on more than 100 COVID-19 trials. It supported the Pfizer/BioNTech vaccine Phase 3 program, helping recruit more than 44,000 patients at 153 sites within four months. Management emphasized that the pandemic’s longer-term operational impact remained uncertain.
- Major subsequent event: On February 24, 2021, ICON agreed to acquire PRA Health Sciences in a cash-and-stock transaction valued at approximately $12 billion: $80 cash and 0.4125 ICON shares per PRA share. Closing was expected in Q3 2021, subject to shareholder and regulatory approvals. ICON arranged committed financing including a bridge facility of up to $6.06 billion; completion, integration, financing and anticipated benefits are subject to risks.
- Debt: The $350 million 2020 Senior Notes comprise $275 million due in 2023 at 2.32% and $75 million due in 2025 at 2.43%. ICON reported compliance with the notes’ financial covenants at year-end. The revolving facility’s LIBOR-based rate creates a transition-related consideration.
- Unusual and contingent items: The restructuring charge included $11.4 million for workforce rationalization and $6.7 million for onerous leases, including $5.4 million of right-of-use asset impairment. A California putative class action alleges labor-law violations; ICON denies wrongdoing and is defending the case, and management did not expect it to materially adversely affect results. No cash dividends were expected in the foreseeable future.
- Principal risks: Customer concentration (top five generated 39.1% of revenue; the largest customer 12.1%), project cancellations and fixed-price cost overruns, reliance on new awards and patient recruitment, pandemic disruption, personnel retention, cybersecurity and privacy, regulation, foreign exchange, and acquisition execution.
Most important facts for investors to verify
- Whether post-pandemic trial activity, client awards and the $6.3 billion performance obligation convert into revenue on the expected schedule.
- Whether margins recover after FY2020’s cost pressures and restructuring, and how much of operating cash flow reflects advance customer billings and working-capital timing.
- The final funding, closing conditions, dilution, integration plan and realized benefits of the proposed PRA acquisition, including the substantial committed bridge financing.
- Customer concentration, contract cost estimates and change-order recovery, and any developments in the California litigation or other contingencies.
- Cash, debt, covenant headroom and capital allocation after share repurchases, planned capital spending and the proposed acquisition.